Abstract | OBJECTIVE: METHODS: A comprehensive review of international diabetes guidelines and a search of medical literature was performed to identify studies presenting data on the use of metformin in pregnancy. The document was approved by the councils of the two scientific societies. RESULTS: In condition affecting the fertility, as PCOS, metformin use in pre-conception or early in pregnancy may be beneficial for clinical pregnancy, even in ART treatment, and in obese-PCOS women may reduce preterm delivery. In obese women, even in the presence of GDM or T2DM, metformin use in pregnancy is associated with a lower gestational weight gain. In pregnancy complicated by diabetes (GDM or T2DM), metformin improves maternal glycemic control and may reduce insulin dose. Neonatal and infant outcomes related to metformin exposure in utero are lacking. Metformin use in women with GDM or T2DM is associated with lower birth weight. However, an increased tendency to overweight- obesity has been observed in children, later in life. CONCLUSIONS:
Metformin may represent a therapeutic option in selected women with obesity, PCOS, GDM, T2DM, and in women undergoing ART. However, more research is required specifically on the long-term effects of in utero exposition to metformin.
|
Authors | Laura Sciacca, Cristina Bianchi, Silvia Burlina, Gloria Formoso, Elisa Manicardi, Maria Angela Sculli, Veronica Resi |
Journal | Acta diabetologica
(Acta Diabetol)
Vol. 60
Issue 10
Pg. 1421-1437
(Oct 2023)
ISSN: 1432-5233 [Electronic] Germany |
PMID | 37401946
(Publication Type: Review, Journal Article)
|
Copyright | © 2023. The Author(s). |
Chemical References |
- Metformin
- Hypoglycemic Agents
|
Topics |
- Pregnancy
- Infant, Newborn
- Child
- Female
- Humans
- Metformin
(therapeutic use, pharmacology)
- Hypoglycemic Agents
(therapeutic use, pharmacology)
- Diabetes Mellitus, Type 2
(drug therapy, epidemiology, complications)
- Diabetes, Gestational
(drug therapy, epidemiology)
- Polycystic Ovary Syndrome
(complications, drug therapy)
- Obesity
(complications, drug therapy, epidemiology)
|